Drug intelligence / Profile preview

HPX-003

Development stage: Preclinical
Lead developer: Hepyx

Overview

HPX-003 is an undisclosed therapeutic asset currently in development by Hepyx. As of early 2024, the company has not publicly released specific information regarding the drug's molecular target, mechanism of action, or primary clinical indications. It is part of a pipeline focused on advanced liver disease, following the company's lead candidate HPX-001, which targets systemic inflammation and hepatocyte proliferation. Due to its status as an undisclosed asset, no clinical phase or modality details are currently available in the public domain.

Beyond the preview

Go deeper on HPX-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HPX-003.

Explore the full profile